查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1983972

CT/NG掃描市場：依技術、產品類型、掃描類型和最終用戶分類－2026-2032年全球市場預測

CT/NG Testing Market by Technology, Product Type, Test Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

CT/NG檢查市場預計到2025年價值18.7億美元，到2026年成長到20.2億美元，到2032年達到33.6億美元，複合年成長率為8.65%。

主要市場統計數據
基準年 2025 18.7億美元
預計年份：2026年 20.2億美元
預測年份 2032 33.6億美元
複合年成長率 (%) 8.65%

本文件概述了披衣菌感染和淋病檢測診斷技術發展的明確策略方向，概述了技術、臨床效用和採購對經營團隊。

本執行摘要對當前披衣菌感染和淋病檢測的臨床診斷趨勢進行了全面的分析回顧，重點關注正在重塑臨床實踐的技術進步、相關人員趨勢和營運挑戰。本文將診斷創新置於更廣泛的醫療服務背景下進行探討，其中診斷準確性、反應時間和與診療路徑的整合日益影響著臨床效用和採購決策。因此，本文旨在向企業主管介紹影響診斷技術應用的關鍵轉折點，並闡明臨床營運和商業策略的實際考量。

分子診斷、多參數檢測和分散式診斷的快速發展如何改變 CT/NG 檢測的臨床工作流程和籌資策略？

分子診斷技術的快速普及、多重檢測需求的日益成長以及對分散式分散式檢查模式使高靈敏度檢測更貼近臨床實務。核酸增幅檢查已從中心檢查室轉移到快速工作流程，這得益於等溫擴增方法的進步和日益強大的聚合酵素鏈鎖反應(PCR) 平台。因此，臨床路徑正在調整，優先考慮那些既能縮短出結果時間又能保持診斷準確性的檢測，這迫使醫療系統和診所重新評估檢測流程和分診通訊協定。

評估 2025 年美國關稅對診斷供應鏈、採購慣例和製造商在地化決策的影響，以及由此產生的營運挑戰。

美國2025年實施的關稅調整的累積影響正對診斷供應鏈、採購決策和製造商的成本結構產生重大影響。進口試劑、儀器和某些組件的關稅調整增加了接收成本，促使買賣雙方重新評估籌資策略並探索替代物流模式。為此，許多相關人員正在加快討論近岸外包、供應商組合多元化以及重新評估庫存緩衝，以維持檢測服務的連續性並應對暫時的價格波動。

綜合細分分析揭示了技術、產品配置、最終用戶需求和測試類型的變化如何相互作用並影響診斷設備的選擇和部署策略。

關鍵的細分洞察揭示了技術選擇、產品形式、最終用戶需求和檢測類型如何相互交織，從而影響技術採納路徑和採購優先順序。技術細分涵蓋培養方法、雜合反應檢測、免疫檢測和核酸增幅檢查。在核酸增幅檢查中，相關人員區分等溫擴增和聚合酵素鏈鎖反應(PCR)。等溫擴增方法包括恒溫環型核酸擴增(LAMP) 和轉錄媒介增幅(TMA)，而聚合酵素鏈鎖反應(PCR) 則可能包括嵌套 PCR 和即時PCR等變體，每種方法在性能、通量和工作流程方面各有優劣。這些技術差異會影響臨床適用性標準和檢查室整合需求，因此在選擇診斷解決方案時，應在評估通訊協定中加以體現。

診斷技術的採用、法規的複雜性以及美洲、歐洲、中東和非洲以及亞太地區採購實務的區域差異，都要求針對每個地區制定相應的商業性方法。

在美洲、歐洲、中東和非洲以及亞太地區，法規環境、臨床應用和供應鏈結構的區域趨勢各不相同，導致製造商和買家的優先事項也存在差異。在美洲，對快速、高靈敏度分子診斷的需求，以及完善的檢查室網路，推動了核酸擴增方法和自動化系統的廣泛應用；然而，採購團隊仍然專注於成本和供應連續性問題。同時，在歐洲、中東和非洲，管理體制的多樣性和醫療基礎設施的差異，使得市場准入面臨許多複雜挑戰，需要製定適應性強的打入市場策略和靈活的驗證方案，以適應不同的認證途徑。

以檢測創新、儀器自動化、數位連接和供應鏈彈性為重點的競爭分析——這些是影響診斷設備製造商成功的關鍵因素。

診斷生態系統中的主要企業正在積極推動檢測方法創新、儀器自動化和數位化連接方面的差異化策略，同時也要應對監管審查和供應鏈限制。成功的企業往往具備強大的開發平臺，專注於開發高靈敏度的核酸擴增和多重檢測方法，並擁有可擴展的耗材和試劑生產能力。同時，投資自動化平台、雜合反應分析儀和PCR儀等能夠簡化工作流程、減少人工操作的儀器，仍是提升營運效率的客戶的關鍵競爭優勢。

為領導者提供可操作的策略建議，以協調研發、製造柔軟性、互通性和客製化的商業模式，從而加速部署並減少受到干擾的風險。

產業領導者應優先考慮整合策略，將技術投資、供應鏈韌性和以客戶為中心的支援相結合，以掌握臨床和商業性機會。首先，研發穩健的核酸擴增檢測方法以及多重和雙重檢測技術，可以提高臨床工作流程的效率，同時滿足臨床對快速、準確和一體化診斷​​的需求。其次，透過近岸外包、契約製造夥伴關係或多元化的供應商網路來增強生產柔軟性，可以降低貿易政策變化所帶來的風險，並減少因單一供應商造成的供應中斷。

嚴謹的多方法研究框架，結合了對關鍵相關人員的訪談、技術分析評估和第二手資料，得出了檢驗且可操作的診斷見解。

本研究採用多面向框架，結合與關鍵相關人員的對話、技術檢測方法的審查以及對二手文獻的整合，以提供可靠且可操作的見解。主要研究包括對實驗室技術人員、臨床決策者、採購經理和監管專家進行結構化訪談，以了解操作限制、檢驗預期和應用促進因素。除這些對話外，還對檢測方法設計、儀器規格和工作流程整合進行了技術審查，以比較不同應用場景下的性能特徵和適用性。

整合診斷趨勢，展現技術融合、營運韌性和精準商業化如何協同運作。這確保了技術的持續應用和臨床影響力。

總之，隨著分子技術、儀器自動化和數據整合技術的融合，CT/NG診斷領域正經歷積極的變革時期，從而改善臨床路徑並提高營運效率。雙重檢測方法的興起和分散式檢查可行性的不斷提高正在重塑檢測的地點和方式，而價格帶來的供應鏈壓力則凸顯了生產柔軟性和採購流程透明度的必要性。綜上所述，這些因素共同描繪出一幅未來圖景：除了技術能力之外，穩健的營運結構和有針對性的商業性舉措對於永續部署也至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 CT/NG 檢查市場：依技術分類

  • 培養方法
  • 雜合反應試驗
  • 免疫檢測
  • 核酸增幅檢查
    • 等溫擴增
      • 恒溫環型核酸擴增
      • 轉錄媒介增幅
    • 聚合酵素鏈鎖反應
      • 嵌套聚合酵素鏈鎖反應
      • 即時聚合酵素鏈鎖反應

第9章：CT/NG檢查市場：依產品類型分類

  • 耗材和試劑
    • 對照材料
    • 成套工具
    • 探針和引子
  • 裝置
    • 自動化系統
    • 雜合反應分析儀
    • 聚合酵素鏈鎖反應（PCR）裝置
  • 軟體和服務

第10章 CT/NG 檢查市場：檢查類型

  • 披衣菌感染檢測
  • 雙重檢查
  • 淋病檢測

第11章 CT/NG 檢查市場：依最終用戶分類

  • 學術研究機構
  • 診所
  • 診斷檢查室
  • 醫院

第12章 CT/NG 檢查市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 CT/NG 檢查市場：依組別

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 CT/NG 檢查市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國CT/NG檢查市場

第16章：中國CT/NG檢測市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Binx Health, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bioneer Corporation
  • Danaher Corporation
  • ELITech Group SAS
  • F. Hoffmann-La Roche Ltd.
  • Geneproof AS
  • Genetic Signatures Ltd.
  • Goffin Molecular Technologies BV
  • Hologic, Inc.
  • Meridian Bioscience Inc.
  • Microbiologics, Inc.
  • Molbio Diagnostics Pvt. Ltd.
  • Operon SA
  • PerkinElmer Inc.
  • QIAGEN NV
  • Sansure Biotech Inc.
  • Seegene, Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Tianlong Technology Co., Ltd.
  • Vircell SL
  • Visby Medical, Inc.
Product Code: MRR-777F3B3232BF

The CT/NG Testing Market was valued at USD 1.87 billion in 2025 and is projected to grow to USD 2.02 billion in 2026, with a CAGR of 8.65%, reaching USD 3.36 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.87 billion
Estimated Year [2026] USD 2.02 billion
Forecast Year [2032] USD 3.36 billion
CAGR (%) 8.65%

A clear and strategic orientation to diagnostic evolution for chlamydia and gonorrhea testing that frames technology, clinical utility, and procurement implications for executives

This executive summary introduces a comprehensive analytical review of current clinical diagnostic dynamics for Chlamydia and Gonorrhea testing, emphasizing technological trajectories, stakeholder behavior, and operational pressures that are reshaping clinical practice. The narrative situates diagnostic innovation within the broader context of healthcare delivery, where diagnostic accuracy, turnaround time and integration with care pathways increasingly determine clinical utility and procurement decisions. As such, this document seeks to orient senior leaders to the critical inflection points influencing diagnostic adoption while clarifying practical considerations for clinical operations and commercial strategy.

Importantly, the introduction frames the diagnostic landscape through multiple lenses: technological capability across culturing methods, hybridization assays, immunoassays and nucleic acid amplification tests; product and service composition including consumables, instruments and software; as well as end-user requirements spanning academic and research institutes, clinics, diagnostic laboratories and hospitals. By establishing this structured perspective, subsequent sections translate technical detail into strategic implications for clinical practice, supply chains and regulatory engagement. As a result, readers should expect clear linkages between diagnostic modalities and real-world deployment scenarios, enabling informed prioritization of investments and partnership opportunities.

How molecular acceleration, multiplex testing, and decentralized diagnostics are collectively reshaping clinical workflows and procurement strategies in CT/NG testing

Transformative shifts in the diagnostic landscape are driven by accelerating molecular adoption, rising demand for multiplexing, and a stronger emphasis on decentralized testing models that bring high-sensitivity assays closer to point-of-care settings. Nucleic acid amplification tests have moved from centralized labs into rapid workflows, supported by advances in isothermal methods and increasingly robust polymerase chain reaction platforms. Consequently, clinical pathways are adapting to favor tests that reduce time-to-result while preserving diagnostic fidelity, prompting health systems and clinics to reassess laboratory routing and triage protocols.

Meanwhile, integration of software and data management tools is changing how test results are interpreted and acted upon, with automated analyzers and connected instruments enhancing throughput and reducing manual errors. This technological shift interacts with evolving regulatory expectations and quality frameworks, requiring manufacturers and laboratory managers to invest in validation, traceability and interoperability. In parallel, the convergence of consumables innovation, assay design and instrument capability is unlocking more practical dual testing strategies, enabling simultaneous detection of Chlamydia trachomatis and Neisseria gonorrhoeae in a single workflow. Together, these dynamics are driving strategic reassessments across clinical, commercial and operational functions, and they demand coordinated responses across R&D, manufacturing and customer support teams.

Assessment of the 2025 United States tariff effects on diagnostic supply chains, procurement practices, and manufacturer localization decisions with operational implications

Cumulative impacts of tariff changes implemented in the United States in 2025 have material consequences for the diagnostic supply chain, procurement decision-making and manufacturer cost structures. Tariff adjustments on imported reagents, instruments and certain components have elevated landed costs, prompting purchasers and suppliers alike to reassess sourcing strategies and to explore alternative logistics models. In response, many stakeholders have accelerated nearshoring discussions, diversified supplier portfolios and re-evaluated inventory buffers to preserve continuity of testing services and to manage episodic price volatility.

These trade policy shifts also influence product roadmaps and investment timelines. Manufacturers that previously relied on low-cost international supply chains are now compelled to examine localized manufacturing or to negotiate revised commercial terms with distributors. As a result, procurement teams are prioritizing greater contractual transparency and longer-term supply agreements to stabilize access to critical consumables and PCR instruments. From a clinical perspective, the tariffs underscore the importance of resilient supply planning: diagnostic laboratories and hospital networks are increasingly focused on identifying validated alternative assays and redundant instrument platforms to mitigate the operational risks associated with constrained reagent availability and fluctuating import costs.

Integrated segmentation analysis reveals how technology variants, product composition, end-user requirements, and test types converge to drive diagnostic selection and implementation strategies

Key segmentation insights illuminate how technology choices, product formats, end-user needs and test types intersect to shape adoption pathways and procurement priorities. Technology segmentation ranges across culturing methods, hybridization assays, immunoassays and nucleic acid amplification tests; within nucleic acid amplification, stakeholders differentiate between isothermal amplification and polymerase chain reaction, while isothermal approaches encompass loop mediated isothermal amplification and transcription mediated amplification and polymerase chain reaction may involve nested PCR and real time PCR variants, each offering distinct performance, throughput and workflow trade-offs. These technological distinctions drive clinical suitability criteria and laboratory integration requirements and should inform evaluation protocols when selecting diagnostic solutions.

Product type segmentation separates consumables and reagents, instruments, and software and services; consumables and reagents include control materials, kits, and probes and primers, while instruments range from automated systems to hybridization analyzers and PCR instruments, and software and services address data management, connectivity and lifecycle support. End-user segmentation identifies academic and research institutes, clinics, diagnostic laboratories and hospitals, each of which has unique throughput demands, accreditation constraints and purchasing cadences that influence product selection. Test type segmentation highlights chlamydia tests, dual tests and gonorrhea tests, with dual tests gaining traction for their operational efficiency and clinical value in settings seeking consolidated diagnostic pathways. Taken together, these segmentation lenses provide a structured way to prioritize investment, validation and commercialization efforts according to target users and use cases.

Regional differentiation in diagnostic adoption, regulatory complexity, and procurement behavior across Americas, Europe, Middle East & Africa, and Asia-Pacific requiring tailored commercial approaches

Regional dynamics vary in regulatory context, clinical adoption, and supply chain architecture across the Americas, Europe, Middle East & Africa, and Asia-Pacific, producing differentiated priorities for manufacturers and purchasers. In the Americas, demand for rapid, high-sensitivity molecular diagnostics and established laboratory networks supports broad adoption of nucleic acid amplification and automated systems, yet procurement teams remain attentive to cost and supply continuity concerns. Conversely, in Europe, Middle East & Africa, heterogeneous regulatory regimes and variable healthcare infrastructure create a mosaic of market entry considerations, necessitating adaptive go-to-market strategies and flexible validation packages that accommodate divergent accreditation pathways.

The Asia-Pacific region exemplifies rapid innovation adoption in certain urban centers alongside significant variability in clinical infrastructure across markets, which amplifies the value of modular instrument platforms and adaptable reagent kits. Across all regions, dual testing modalities and point-of-care options are becoming increasingly relevant as health systems prioritize streamlined patient pathways and reduced follow-up visits. Furthermore, regional procurement policies, public health screening programs and reimbursement environments continue to shape end-user purchasing behavior, underscoring the need for tailored commercial models, local partnerships and regulatory preparedness to succeed across diverse geographies.

Competitive capabilities analysis highlighting assay innovation, instrument automation, digital connectivity, and supply resilience that define success for diagnostic companies

Leading companies in the diagnostic ecosystem are advancing differentiated strategies across assay innovation, instrument automation, and digital connectivity, while simultaneously navigating regulatory scrutiny and supply chain constraints. Successful players are those that pair robust R&D pipelines-focused on high-sensitivity nucleic acid amplification and multiplex assay development-with scalable manufacturing capabilities for consumables and reagents. In parallel, investment in automated platforms, hybridization analyzers and PCR instruments that simplify workflow adoption and reduce hands-on time remains a principal differentiator for customers seeking operational efficiency.

Strategic partnerships and OEM arrangements are increasingly common as firms seek to accelerate time-to-market and broaden distribution reach. Companies that augment product offerings with software and services that enable result management, analytics and compliance support tend to achieve deeper integration within health systems. Additionally, those that maintain flexible supply models and transparent quality systems are better positioned to reassure large institutional customers and to respond to procurement tenders. Taken together, these capabilities-innovation, scale, connectivity and supply resilience-constitute the core attributes that define competitive advantage in the current CT/NG diagnostic landscape.

Actionable strategy recommendations for leaders to align R&D, manufacturing flexibility, interoperability, and tailored commercial models to accelerate adoption and reduce exposure to disruption

Industry leaders should prioritize an integrated strategy that aligns technological investments, supply chain resilience, and customer-centric support to capture clinical and commercial opportunities. First, directing R&D toward robust nucleic acid amplification assays and multiplex or dual test formats will meet clinical demand for rapid, accurate and consolidated diagnostics while improving clinical workflow efficiency. Second, strengthening manufacturing flexibility-either through nearshoring, contract manufacturing partnerships, or diversified supplier networks-will mitigate risks tied to trade policy changes and reduce exposure to single-source disruptions.

In addition, companies should enhance instrument and software interoperability to lower barriers to adoption among laboratories and clinics that operate heterogeneous analyzer fleets. Strategic investments in regulatory intelligence and expedited validation pathways will facilitate quicker market access across diverse geographies. Furthermore, building tailored commercial models for academic and research institutes, clinics, diagnostic laboratories and hospitals-each with their own purchasing rhythms-will improve conversion and retention. Finally, pursuing collaborative initiatives with public health programs and clinical networks can reinforce credibility and accelerate uptake, especially for dual testing solutions that offer immediate operational value in screening and treatment workflows.

A rigorous multi-method research framework combining primary stakeholder interviews, technical assay evaluation, and secondary evidence to produce validated, actionable diagnostic insights

The research approach employed a multi-method framework combining primary stakeholder engagement, technical assay review and secondary literature synthesis to deliver robust, actionable insights. Primary research included structured interviews with laboratorians, clinical decision-makers, procurement leaders and regulatory specialists to capture operational constraints, validation expectations and adoption drivers. These engagements were complemented by technical reviews of assay design, instrument specifications and workflow integration to compare performance characteristics and suitability across different use cases.

Secondary research drew on public regulatory documentation, clinical guidelines and peer-reviewed literature to contextualize clinical utility and evidence standards for nucleic acid amplification, hybridization assays and immunoassays. Data synthesis relied on triangulation across sources to validate thematic findings and to surface consistent operational patterns. Quality assurance measures included cross-validation of interview insights, methodical documentation of data provenance, and internal peer review to ensure analytical rigor. This layered methodology ensures that conclusions and recommendations are grounded in real-world practice while remaining sensitive to regulatory and supply chain realities.

Synthesis of diagnostic trends showing how technology convergence, operational resilience, and targeted commercialization must align to sustain adoption and clinical impact

In conclusion, the CT/NG diagnostic landscape is in active transition as molecular techniques, instrument automation and data integration converge to improve clinical pathways and operational efficiency. The rise of dual testing approaches and the increasing feasibility of decentralized testing are reshaping where and how testing occurs, while tariff-driven supply chain pressures emphasize the need for manufacturing flexibility and procurement transparency. Taken together, these themes point to a future in which technological capability must be matched by resilient operations and targeted commercial engagement to achieve sustainable adoption.

For decision-makers, the imperative is clear: align product development and commercialization plans with the practical constraints of end-users, regional regulatory environments and supply chain realities. By doing so, organizations can accelerate clinical impact, strengthen customer relationships and reduce operational risk. The path forward requires coordinated investment across assay innovation, instrument interoperability and supply network design, alongside proactive regulatory planning and tailored go-to-market strategies that reflect the nuanced needs of academic institutions, clinical laboratories, clinics and hospitals.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CT/NG Testing Market, by Technology

  • 8.1. Culturing Methods
  • 8.2. Hybridization Assays
  • 8.3. Immunoassays
  • 8.4. Nucleic Acid Amplification Tests
    • 8.4.1. Isothermal Amplification
      • 8.4.1.1. Loop Mediated Isothermal Amplification
      • 8.4.1.2. Transcription Mediated Amplification
    • 8.4.2. Polymerase Chain Reaction
      • 8.4.2.1. Nested Polymerase Chain Reaction
      • 8.4.2.2. Real Time Polymerase Chain Reaction

9. CT/NG Testing Market, by Product Type

  • 9.1. Consumables And Reagents
    • 9.1.1. Control Materials
    • 9.1.2. Kits
    • 9.1.3. Probes And Primers
  • 9.2. Instruments
    • 9.2.1. Automated Systems
    • 9.2.2. Hybridization Analyzers
    • 9.2.3. Polymerase Chain Reaction Instruments
  • 9.3. Software And Services

10. CT/NG Testing Market, by Test Type

  • 10.1. Chlamydia Tests
  • 10.2. Dual Tests
  • 10.3. Gonorrhea Tests

11. CT/NG Testing Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Clinics
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals

12. CT/NG Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. CT/NG Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. CT/NG Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States CT/NG Testing Market

16. China CT/NG Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Becton, Dickinson and Company
  • 17.7. Binx Health, Inc.
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. Bioneer Corporation
  • 17.10. Danaher Corporation
  • 17.11. ELITech Group SAS
  • 17.12. F. Hoffmann-La Roche Ltd.
  • 17.13. Geneproof A.S.
  • 17.14. Genetic Signatures Ltd.
  • 17.15. Goffin Molecular Technologies B.V.
  • 17.16. Hologic, Inc.
  • 17.17. Meridian Bioscience Inc.
  • 17.18. Microbiologics, Inc.
  • 17.19. Molbio Diagnostics Pvt. Ltd.
  • 17.20. Operon S.A.
  • 17.21. PerkinElmer Inc.
  • 17.22. QIAGEN N.V.
  • 17.23. Sansure Biotech Inc.
  • 17.24. Seegene, Inc.
  • 17.25. Siemens Healthineers AG
  • 17.26. Thermo Fisher Scientific Inc.
  • 17.27. Tianlong Technology Co., Ltd.
  • 17.28. Vircell S.L.
  • 17.29. Visby Medical, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CT/NG TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CT/NG TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CT/NG TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CT/NG TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CT/NG TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CT/NG TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CT/NG TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CT/NG TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CT/NG TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CT/NG TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CT/NG TESTING MARKET SIZE, BY CULTURING METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CT/NG TESTING MARKET SIZE, BY CULTURING METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CT/NG TESTING MARKET SIZE, BY CULTURING METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CT/NG TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CT/NG TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CT/NG TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CT/NG TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CT/NG TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CT/NG TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CT/NG TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CT/NG TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CT/NG TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CT/NG TESTING MARKET SIZE, BY NESTED POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CT/NG TESTING MARKET SIZE, BY NESTED POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CT/NG TESTING MARKET SIZE, BY NESTED POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CT/NG TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CT/NG TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CT/NG TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CT/NG TESTING MARKET SIZE, BY CONTROL MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CT/NG TESTING MARKET SIZE, BY CONTROL MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CT/NG TESTING MARKET SIZE, BY CONTROL MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CT/NG TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CT/NG TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CT/NG TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CT/NG TESTING MARKET SIZE, BY PROBES AND PRIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CT/NG TESTING MARKET SIZE, BY PROBES AND PRIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CT/NG TESTING MARKET SIZE, BY PROBES AND PRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CT/NG TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CT/NG TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CT/NG TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CT/NG TESTING MARKET SIZE, BY HYBRIDIZATION ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CT/NG TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CT/NG TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CT/NG TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CT/NG TESTING MARKET SIZE, BY CHLAMYDIA TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CT/NG TESTING MARKET SIZE, BY CHLAMYDIA TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CT/NG TESTING MARKET SIZE, BY CHLAMYDIA TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CT/NG TESTING MARKET SIZE, BY DUAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CT/NG TESTING MARKET SIZE, BY DUAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CT/NG TESTING MARKET SIZE, BY DUAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CT/NG TESTING MARKET SIZE, BY GONORRHEA TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CT/NG TESTING MARKET SIZE, BY GONORRHEA TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CT/NG TESTING MARKET SIZE, BY GONORRHEA TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CT/NG TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CT/NG TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CT/NG TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CT/NG TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CT/NG TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CT/NG TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CT/NG TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CT/NG TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CT/NG TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CT/NG TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CT/NG TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CT/NG TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CT/NG TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CT/NG TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CT/NG TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. G7 CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. G7 CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. G7 CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 219. G7 CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 225. NATO CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. NATO CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 228. NATO CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 229. NATO CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. NATO CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL CT/NG TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CT/NG TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA CT/NG TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA CT/NG TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA CT/NG TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA CT/NG TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA CT/NG TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA CT/NG TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA CT/NG TESTING MARKET SIZE, BY CONSUMABLES AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA CT/NG TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA CT/NG TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA CT/NG TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)